TITLE

TEVA SIGNS PACT TO BUY HONEYWELL PHARMACEUTICAL IN ITALY

PUB. DATE
July 2002
SOURCE
Worldwide Biotech;Jul2002, Vol. 14 Issue 7, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the acquisition of Honeywell Pharmaceutical Fine Chemicals S.r.l by Teva Pharmaceutical Industries Ltd.
ACCESSION #
6939473

 

Related Articles

  • Teva Buys Honeywell Italian Pharma Unit.  // Chemical Market Reporter;5/27/2002, Vol. 261 Issue 21, p3 

    Deals with the plan of Teva Pharmaceutical Industries Ltd. to acquire Honeywell Pharmaceutical Fine Chemicals (HPFC) SrL. in June 2002. Background on the operations of HPFC; Reasons for the acquisition; Details on the purchase of Bayer Classics by Teva in April 2002.

  • Teva Pharmaceuticals USA. Rankin, Ken // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP16 

    Profiles Kulpsville, Pennsylvania-based generic drug company Teva Pharmaceutical Industries Ltd. Contact information; Financial performance; Company history; Business profile.

  • Teva markets some of top generics.  // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP54 

    Reports on developments related to Teva Pharmaceutical Industries Ltd. Drugs marketed; Business operations in the United States; Company profile.

  • Focusing on new products, partnering.  // Drug Store News;2/16/98, Vol. 20 Issue 3, pCP12 

    Profiles Sellersville, Pennsylvania-based Teva Pharmaceuticals Industries Ltd. New product strategy by the company for 1998; Partnerships being planned by the company; Comment by Bill Fletcher, chief executive officer of the company.

  • Honeywell develops extra-rigid nylon 6.  // Plastics News;02/28/2000, Vol. 11 Issue 54, p21 

    Focuses on Honeywell Engineered Applications & Solutions' development of an extra-rigid nylon 6 for high performance applications.

  • TEVA GETS FIRST FDA APPROVAL OF KETOCONAZOLE 2% CREAM.  // Worldwide Biotech;Jun2000, Vol. 12 Issue 6, p7 

    Reports that Teva Pharmaceutical Industries Ltd. has received from the United States Food and Drug Administration an approval to manufacture and market Ketoconazole 2% Cream.

  • Teva Pharmaceutical slammer dunk. Goldgaber, Arthur; Allaux, Jean-Francois // Financial World;4/15/97, Vol. 166 Issue 4, p26 

    Reports about the prospects of investing in Teva Pharmaceutical Industries, a company based in Petach Tikva, Israel. Introduction of Copaxone in the market; Anticipated increase in Teva's sales due to Copaxone and the launching of generic drugs; Confidence of Bennett Zimmerman and investors in...

  • Market briefs. Lerner, Matthew // Chemical Market Reporter;08/18/97, Vol. 252 Issue 7, p13 

    Reports that Teva Pharmaceutical Industries Ltd. has recalled five batches of clindamycin, a semi-synthetic antibiotic, after the United States Food & Drug Administration found certain deficiencies in the qualification of the raw material used to make the drugs.

  • Teva Announces Debut Of Naproxen Time-release Tablets.  // Drug Store News;10/19/98, Vol. 20 Issue 17, pCP49 

    Announces the availability of Teva Pharmaceuticals USA's Naproxen delayed-release tablets. Cost-savings alternative to the brand product.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics